Positioning biologic agents in the treatment of Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 10, 2009, Pages 1570-1582

  Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Biologic therapies; Crohn's disease; Immunomodulators

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; STEROID;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC VARIABILITY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE; TUBERCULOSIS;

BIOLOGICAL THERAPY; CROHN DISEASE; HUMANS;

EID: 70449469801     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20918     Document Type: Review

References (72)

1. Hanauer SB. Turning traditional treatment strategies on their heads: current evidence for 'step-up' versus 'top-down.' Rev Gastroenterol Disord. 2007;7(suppl 2):S17-S22.
2. Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. (Pubitemid 44246602)
3. Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007;133:312-339. (Pubitemid 47031141)
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
5. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869. (Pubitemid 40523539)
6. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413. (Pubitemid 38182297)
7. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60. (Pubitemid 34123864)
8. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
9. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330. (Pubitemid 43972900)
10. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260. (Pubitemid 32729372)
11. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. (Pubitemid 40139240)
12. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther. 2007;25:59-65. (Pubitemid 44902864)
13. Wolters FL, Russel MG, Sijbrandij J, et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol. 2006;41(suppl 243):46-54. (Pubitemid 43941066)
14. Freeman HJ. Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence. Can J Gastroenterol. 2004;18:661-665.
15. Vermeire S, van Assche G, Rutgeerts P. Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. (Pubitemid 44902859)
16. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006;130:1069-1077.
17. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947-953. (Pubitemid 34408253)
18. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
19. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367. (Pubitemid 43381681)
20. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007;56:1181-1183.
21. Sandborn WJ, Rugeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab and azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol. 2008; Abstract 29.
22. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. (Pubitemid 47300424)
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
24. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902. (Pubitemid 30777909)
25. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
26. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci.2006;51:1516-1524. (Pubitemid 44379292)
27. Faubion WA. Step-up versus top-down: application of new biological agents in pediatric inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1094-1096.
28. Tung J, Loftus EV, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Gastroenterology. 2005;4(suppl 2):A327.
29. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-1123. (Pubitemid 44311638)
30. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-1129. (Pubitemid 44311642)
31. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
32. Lémann M, Mary JY, Duclos B, et al, and the Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061.
33. Targan SR, Hanauer SB, van Deventer SJ, et al, on behalf of the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
34. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405. (Pubitemid 29205403)
35. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22-28. (Pubitemid 29013489)
36. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034. (Pubitemid 29203012)
37. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442. (Pubitemid 43261469)
38. D'Haens G, Baert F, van Assche G, et al, for the Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
39. Feagan B, McDonald JW, Panaccione R, et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology. 2008;135:294-295.
40. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333. (Pubitemid 43202032)
41. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med. 2007;146:829-838. (Pubitemid 351650483)
42. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP87) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818. (Pubitemid 41242673)
43. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238. (Pubitemid 47080387)
44. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250. (Pubitemid 47080388)
45. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553. (Pubitemid 38834038)
46. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231. (Pubitemid 47300423)
47. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608. (Pubitemid 36204954)
48. Sandborn WJ, Colombel JF, Enns R, et al, on behalf of the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; and Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
49. Targan SR, Feagan BG, Fedorak RN, et al, on behalf of the International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
50. Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis. 2007;13:769-796.
51. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. Arthritis Rheum. 2006;54:1075-1086.
52. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(suppl 4):16-22.
53. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:926-936.
54. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut. 2008;57:1393-1397.
55. Mackey AC, Green L, Liang L, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastro Nutr. 2007;44:265-267. (Pubitemid 46175082)
56. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. (Pubitemid 47309975)
57. Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22:370-376. (Pubitemid 44090191)
58. Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top:down or step-up? Dig Dis. 2007;25:260-266. (Pubitemid 350194180)
59. Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712-2718. (Pubitemid 38020113)
60. Saito H, Fukuda Y, Katsuragi K, et al. Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis. Gut. 2003;52:535-540. (Pubitemid 36363407)
61. Gupta SK, Fitzgerald JF, Croffie JM, et al. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis. 2004;10:240-244. (Pubitemid 38618253)
62. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004;4:167-174. (Pubitemid 40012216)
63. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
64. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378. (Pubitemid 44142445)
65. Dotan N, Altstock RT, Schwarz M, et al. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006;15:442-450. (Pubitemid 44147091)
66. Mow WS, Vasiliauskas EA, Lin Y-C, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
67. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68. (Pubitemid 46719135)
68. Yamamoto-Furusho JK. Genetic factors associated with the development of inflammatory bowel disease. World J Gastroenterol. 2007;13:5594-5597. (Pubitemid 350031479)
69. Torok HP, Glas J, Lohse P, et al. Genetic variants and the risk of Crohn's disease: what does it mean for future disease management? Expert Opin Pharmacother. 2006;7:1591-1602. (Pubitemid 44209603)
70. Odes S, Friger M, Vardi H, et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis. 2007;13:874-881. (Pubitemid 47203865)
71. Hancock L, Ahmad T, Reckley JB, et al. Clinical and molecular characteristics of isolated colonic Crohn's disease (CD). Gastroenterology. 2006;130(suppl 2):A589.
72. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-466. (Pubitemid 351733422)